Furosemide was first synthesised in the early 1960s and has remained on the World Health Organisation's List of Essential Medicines continuously since the first edition in 1977, a distinction that reflects both its clinical utility and the maturity of its manufacturing base. The molecule, chemically described as 4-chloro-2-(furan-2-ylmethylamino)-5-sulfamoylbenzoic acid, is produced commercially through a multi-step organic synthesis that has been refined over six decades into a well-characterised, GMP-certifiable process. Indian API manufacturers currently account for a significant share of global furosemide API production, with output supplying generic finished dose manufacturers across the US, EU, GCC, and emerging markets.
For pharmaceutical buyers evaluating a furosemide API manufacturing company, understanding the production process is not an academic exercise. The synthesis route determines the impurity profile. The impurity profile determines the analytical testing burden on the finished dose manufacturer. The quality management system surrounding the synthesis determines whether the batch-to-batch consistency required for regulatory filings and commercial production is achievable at scale. This guide covers each stage of furosemide API manufacture from starting materials through to packaged bulk supply, with the technical detail that procurement teams and formulation scientists need to qualify a manufacturer and place a production-scale order with confidence.
The Chemistry Behind Furosemide API Synthesis
Furosemide API is synthesised through a condensed multi-step reaction sequence starting from anthranilic acid derivatives and furan-2-ylmethylamine (furfurylamine). The principal industrial synthesis route proceeds through three defined stages: chlorosulfonation of a substituted aniline starting material to introduce the sulfonamide group, amination with furfurylamine to establish the secondary amine linkage, and cyclisation with saponification steps to yield the carboxylic acid functionality that defines the final molecular structure.
The reaction intermediates in this route include chlorinated and sulfonated aniline derivatives that are themselves subject to control under ICH Q11 (Development and Manufacture of Drug Substances), which requires manufacturers to identify and justify the designated starting materials for the synthesis and to demonstrate control of relevant attributes through all subsequent steps. Indian manufacturers using this principal route typically designate the sulfonation product as the regulatory starting material, with all subsequent steps conducted under full GMP conditions as defined in ICH Q7 (Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients).
An alternative synthesis route, used by a smaller number of manufacturers, proceeds via a Schotten-Baumann acylation sequence. The end molecular specification is identical regardless of route, but the impurity profile differs because different synthetic pathways generate different process-related impurities. Buyers qualifying a new furosemide API supplier should always obtain the impurity profile specific to that supplier's route, not assume it matches a reference standard derived from a different synthesis.
GMP Requirements for Furosemide API Manufacture
ICH Q7 as the Global Standard
The manufacture of furosemide API for regulated market supply must comply with ICH Q7, the internationally harmonised GMP standard for active pharmaceutical ingredients. ICH Q7 is adopted by reference in US FDA regulations (21 CFR Part 211 and related guidance), EU GMP Part II (EudraLex Volume 4), and the GMP guidelines of the UK MHRA, WHO, and most national regulatory authorities that operate inspection programmes for pharmaceutical manufacturing.
ICH Q7 compliance requires that furosemide API manufacture is conducted under a documented quality management system covering personnel qualifications, equipment qualification and calibration, raw material control, in-process controls, batch documentation, deviation management, change control, and product release. For Indian manufacturers exporting to the US, EU, or GCC, the quality management system must be capable of withstanding an on-site regulatory inspection, and the inspection record must be current: US FDA facility registrations lapse after 12 months without renewal, and EU GMP certificates typically carry a three-year validity.
Critical In-Process Controls
The furosemide API synthesis involves exothermic reaction steps and intermediate isolation points where in-process controls are required to confirm reaction completion and intermediate quality before advancing to the next step. Key in-process controls for the principal synthesis route include pH monitoring during the sulfonation step, reaction completion assay by thin-layer chromatography or HPLC before the amination step, yield and purity checks at intermediate isolation, and moisture content measurement before the final drying step.
The final API is dried using fluid bed drying or tray drying equipment to achieve the loss on drying specification, typically not more than 0.5 percent as per the Ph.Eur. monograph. Over-drying can affect particle size distribution, which has downstream implications for dissolution performance in oral solid dosage forms. Under-drying risks microbial and chemical stability in storage. GMP-compliant manufacturers document drying parameters (temperature, duration, airflow) as part of the batch manufacturing record and verify the result with an in-process moisture assay before batch release.
Impurity Profile and Control Strategy
Furosemide API impurity control is governed by three overlapping regulatory frameworks. ICH Q3A sets limits for identified and unidentified process-related impurities in new drug substances, with the reporting threshold at 0.05 percent, the identification threshold at 0.10 percent, and the qualification threshold at 0.15 percent for a maximum daily dose above 2 grams. ICH Q3C governs residual solvents used in the synthesis, with Class 2 solvents (including commonly used process solvents such as dimethylformamide and acetonitrile) carrying defined permitted daily exposure limits. The relevant pharmacopoeial monograph, Ph.Eur. 0391 for furosemide, specifies limits for related substances under a gradient HPLC method, with individual specified impurities limited to not more than 0.2 percent and total impurities limited to not more than 0.5 percent.
The known furosemide-related impurities include the des-chloro analogue, the diacid derivative formed through carboxylation side reactions, and furfurylamine-related compounds arising from incomplete reaction or degradation. A mature manufacturing process at a reputable furosemide API manufacturing company will have characterised and specified limits for each identified impurity, with the impurity profile documented in the drug substance specification and reported on the Certificate of Analysis. Buyers should request the impurity profile as part of supplier qualification, not just the summary COA, to confirm that the supplier's controlled impurities match those relevant to the intended finished dosage form and target market.
Genotoxic impurity assessment is an additional consideration for furosemide API manufactured via routes involving chlorinated intermediates. ICH M7 requires that mutagenic impurities be identified, assessed, and controlled to limits consistent with acceptable lifetime cancer risk (typically below 1.5 micrograms per day intake). Manufacturers should be able to demonstrate either that genotoxic impurities are absent above the threshold of toxicological concern or that specific controls are in place to purge them during downstream processing steps.
Analytical Testing at Release
A cGMP-certified furosemide API manufacturing company releases each batch against a defined specification that includes, at minimum, the tests and limits set in the relevant pharmacopoeial monograph plus any additional in-house tests required by the manufacturing process or by specific customer or regulatory requirements. For furosemide API, the standard release testing panel covers identification (infrared spectroscopy or HPLC retention time comparison), assay (HPLC, not less than 98.0 percent and not more than 101.0 percent on the dried basis, per Ph.Eur. 0391), related substances (gradient HPLC), loss on drying, sulphated ash, heavy metals (or elemental impurities per ICH Q3D), residual solvents (gas chromatography headspace method), and microbial limits.
Particle size distribution is not a compendial release test for furosemide API under the Ph.Eur. monograph, but is increasingly specified by customers as an additional release parameter because particle size directly affects dissolution rate in oral solid dosage forms. Manufacturers supplying customers who specify particle size should perform laser diffraction analysis (typically D10, D50, and D90 values by volume) as a release test and include results on the COA. Buyers should confirm whether particle size is included in the supplier's standard release specification or requires a separate request and surcharge.
Packaging Specifications for Bulk Export
Furosemide API for bulk export from India is typically packaged in double-polyethylene-lined, UN-approved fibre drums with a net content of 5 kg, 10 kg, or 25 kg per drum. For high-volume orders, HDPE drums with inner polyethylene liners at 25 kg fill weight are an alternative that some buyers prefer for reduced packaging waste. The inner polyethylene liner is heat-sealed; the outer drum is sealed with a metal clip or bolt-ring lid and labelled with batch number, manufacturing date, retest date, storage conditions, net weight, and regulatory symbols.
Each drum in a commercial shipment is assigned a unique container identifier traceable to the batch manufacturing record. The packing list issued with the shipment documents the container identifier, drum weight (gross and net), and batch number for each unit. Buyers who receive furosemide API into a GMP warehouse are required under their own GMP obligations to verify the physical integrity and labelling of each container against the packing list and COA before accepting the batch into quarantine.
Storage conditions stated on the label follow ICH Q1A(R2): controlled temperature not exceeding 30 degrees Celsius, protected from light. Shelf life from the manufacturing date to the retest date is typically 24 to 36 months for compliant product stored under appropriate conditions, with the retest date supported by stability data from the manufacturer's ICH stability programme.
What the Manufacturing Process Tells You About the Supplier
A well-documented, GMP-compliant furosemide API manufacturing process is not just a quality assurance mechanism. It is a commercial signal. A manufacturer who can produce a complete batch manufacturing record, an impurity profile with identified and qualified compounds, a validated analytical test package, and a current regulatory inspection clearance has made the capital and operational investment required to be a reliable long-term supplier. That investment does not happen at low-cost, low-compliance operations.
The converse is also true. Furosemide API supplied without a documented impurity profile, from a facility with an unresolved FDA Warning Letter or EU GMP suspension, at a price point that cannot support a compliant quality management system, is a procurement risk that will eventually surface as a production stoppage, a regulatory rejection, or a recall. The manufacturing process is the product. What happens between the starting materials and the packaged drum is what determines whether the furosemide API a buyer receives is fit for use in a regulated market finished dosage form, or is not.
Kodel Life manufactures furosemide API under a cGMP-certified quality system with full batch documentation, an ICH-compliant impurity control strategy, and regulatory support for US, EU, and GCC market buyers. Plant visits and technical Zoom calls with the quality and manufacturing team are available on request through the product page.
